- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05889390
Neoadjuvant Concomitant Modulated Electro-hyperthermia in HER2-negative Breast Cancer (NeoHTerMa)
[A Prospective, Randomized Trial to Assess the Added Value of Concomitant Modulated Electro-hyperthermia in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy - an Investigator Initiated Study]
Study Overview
Status
Conditions
Detailed Description
This study is a pivotal, randomized (1:1), open-label, two-treatment group, single-centre trial of Oncotherm EHY-2030, a modulated electro-hyperthermia (mEHT) device. Female patients aged 18 years or older with locally advanced, unilaterally localized HER2-negative breast cancer requiring neoadjuvant treatment are eligible for the study.
In the study, the wTAX (+ carboplatin) +AC neoadjuvant chemotherapy protocol will be administered according to the routine daily regimen, with or without mEHT three times a week during the wTAX (+ carboplatin) period. Carboplatin will be administered for patients with triple-negative breast cancer only.
Primary objective: to compare whether the percentage of tumor size decrease determined by imaging techniques is different in the two treatment groups?
Secondary and other objectives:
- Is complete pathological response (pCR) more common in the mEHT-treated group?
- Does the pattern of treatment response (pCR : pPR : pNR) differ between the two groups?
- Is the quality of life of patients different in the two study groups?
- Is there any treatment-related changes in the routine laboratory parameters such as blood count, liver enzymes, renal function? And do these differ in the two study arms?
- Safety and tolerability analysis of the device.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Contact
- Name: Attila M Szasz, M.D./Ph.D.
- Phone Number: 51618 +3614591500
- Email: szasz.attila_marcell@med.semmelweis-univ.hu
Study Contact Backup
- Name: Zoltan Herold, Ph.D.
- Phone Number: +3614591500
- Email: herold.zoltan@med.semmelweis-univ.hu
Study Locations
-
-
-
Budapest, Hungary, 1083
- Recruiting
- Division of Oncology, Department of Internal Medicine and Oncology, Semmelweis University
-
Contact:
- Attila M Szasz, M.D./Ph.D.
- Phone Number: 51618 +3614591500
- Email: szasz.attila_marcell@med.semmelweis-univ.hu
-
Contact:
- Zoltan Herold, Ph.D.
- Phone Number: +3614591500
- Email: herold.zoltan@med.semmelweis-univ.hu
-
Principal Investigator:
- Magdolna Dank, M.D./Ph.D.
-
Sub-Investigator:
- Gyöngyvér Szentmártoni, M.D./Ph.D.
-
Sub-Investigator:
- Magdolna Herold
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- At least 18 years of age
- Female patient
- Life expectancy ≥ 6 months
- De novo histological/cytological diagnosis of HER2-negative (triple-negative or ER/PR+) breast tumor involving one breast
- Diagnosis of breast tumor ≤ 40 days
Locally advanced stage disease (stage II and III) requiring neoadjuvant treatment - according to the following criteria:
- Primary breast tumor ≥ 20 mm in size and/or
- Presence of axillary lymph node metastases
- Optimal surgical intervention without neoadjuvant chemotherapy is not feasible
- ECOG status: 0-2
- Suitable for and designated by the investigator for neoadjuvant therapy with wTAX + (carboplatin) + AC chemotherapeutic agent
- Willingness to participate in the trial and signed the informed consent form for the protocol
Exclusion Criteria:
- Patient is ≤ 18 years of age.
- Tumor of both breasts.
- Diagnosis of breast tumor > 40 days
- HER2 positive breast tumor
- Has already received some anticancer therapy
- Any previous cancer requiring anti-tumor treatment within 5 years prior to selection, except: in situ cervical or uterine cancer and non-melanoma skin cancer.
Co-existing serious diseases:
- Presence of severe neuropathy requiring medical treatment, diabetic neuropathy.
Clinically significant hematological, hepatic or renal dysfunction, as defined below:
- Neutrophil count < 1.5 G/L and platelet count < 100 G/L
- bilirubin > 1.5 times the upper limit of normal range (ULN), except for known Gilbert's disease
- AST and/or ALT > 2.5 times the upper limit of the normal range
- Serum creatinine > 1.5 times the upper limit of the normal range.
- Clinically significant cardiovascular disease in the medical history, unless the disease is adequately controlled. E.g. New York Heart Association (NYHA) Class II or worse congestive heart failure (moderate limitation of physical activity; well-being at rest but normal activity is associated with fatigue, rapid heart rate or dyspnoea).
- Uncontrolled hypertension with resting systolic ≥ 180 mmHg, resting diastolic ≥ 110 mmHg.
- Resting sinus tachycardia with a pulse ≥ 110/min.
- History of sympathetic or treatment-naive cardiac arrhythmia. Atrial fibrillation or flutter controlled with medication is not an exclusion for participation in the study.
- Major cardiovascular event (e.g. myocardial infarction, unstable angina, cerebral vascular accident (CVA), etc.) in the 6 months prior to randomisation.
Active infection or severe underlying disease that renders the patient unfit for treatment according to the study protocol.
- A current diagnosis of chronic hepatitis, Hepatitis B surface antigen positive, Hepatitis C antibody positive and/or other clinically active liver disease requiring treatment.
- Known HIV infection.
- Untreated thyroid disease.
- Systemic autoimmune disease.
- Any psychiatric condition in the medical history that may result in the patient being unable to understand or comply with the requirements of the study, having reduced communication skills or being unable to give informed consent.
- Need for concomitant anti-tumor therapy in addition to wTAX + (carboplatin) + AC protocol
- Any active medical device implanted in the anatomical area, such as pacemakers.
- Known severe hypersensitivity to any of the chemotherapies used in the study.
- Pregnancy or breast-feeding (patients of childbearing potential must use effective contraception throughout the study and for 3 months after the end of treatment). The method of effective contraception is at the discretion of the investigator.
- History of drug or alcohol dependence within 6 months prior to screening.
- Unable to comply with the study plan for medical, psychological, family, geographical or other reasons.
- Institutionalisation by administrative or judicial decision.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: wTAX (+ carboplatin) +AC
|
weekly paclitaxel for 12 weeks
added to weekly paclitaxel if patient has triple-negative breast cancer
according to the AC protocol
Either breast-conserving surgery or total mastectomy after the neoadjuvant chemotherapy with or without mEHT (if feasible)
|
Experimental: wTAX (+ carboplatin) +AC + mEHT
|
weekly paclitaxel for 12 weeks
added to weekly paclitaxel if patient has triple-negative breast cancer
according to the AC protocol
Either breast-conserving surgery or total mastectomy after the neoadjuvant chemotherapy with or without mEHT (if feasible)
Oncotherm EHY-2030 is a non-invasive electromagnetic devices with known anti-tumoral effects.
It operates in a precision capacitive coupled impedance matched way, working on a radiofrequency of 13.56 MHz.
mEHT exploits various biophysical differences of cancer cells.
For example, energy absorption on the membrane rafts is different than those of healthy host cells, and damage-associated molecular patterns (DAMPS) will also occur leading to programmed or immunogenic tumor cell death.
mEHT can enhance DNA fragmentation of tumor cells, increase the fraction of cells with low mitochondrial membrane potential, increase the concentration of intracellular Ca2+, increase the Fas, c-Jun N-terminal kinases and MAPK/ERK signaling pathways, increase the expression of pro-apoptotic Bcl-2 family proteins and can up-regulate the expression of genes associated with the molecular function of cell death (EGR1, JUN, and CDKN1A) and silencing others associated with cytoprotective functions.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Residual size of the primary tumor, determined by imaging techniques (in percentage)
Time Frame: change from baseline at 6 months
|
Using breast MR measurements, the the residual size of the primary tumor will be specified for all patients (in percentage). The comparison of these between the two study arms will serve as the primary outcome measure. Calculation: The tumor size after the 6-months treatment period (in mm) will be divided by the size measured prior treatment (in mm). The quotient will be given as a percentage and subtracted from 100. |
change from baseline at 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of complete pathological response
Time Frame: 9 months
|
Comparison of the percentage of complete pathological responses between the two groups
|
9 months
|
Treatment response patterns
Time Frame: 9 months
|
Comparison of the pathological response categories (pCR : pPR : pNR) between the two groups
|
9 months
|
Comparison of surgical procedure ratios
Time Frame: 9 months
|
It will be compared whether the ratio of two main breast surgery types (breast-conserving surgery vs. total mastectomy) differ between the two study arms.
|
9 months
|
Effect of treatment on white blood cell counts
Time Frame: through study completion, an average of ~8 months
|
White blood cell counts (in G/L) will be measeured at every patient visit, and their longitudinal change will be analyzed using mixed-effect statistical modeling techniques.
|
through study completion, an average of ~8 months
|
Effect of treatment on red blood cell counts
Time Frame: through study completion, an average of ~8 months
|
Red blood cell counts (in T/L) will be measeured at every patient visit, and their longitudinal change will be analyzed using mixed-effect statistical modeling techniques.
|
through study completion, an average of ~8 months
|
Effect of treatment on platelet counts
Time Frame: through study completion, an average of ~8 months
|
Platelet counts (in G/L) will be measeured at every patient visit, and their longitudinal change will be analyzed using mixed-effect statistical modeling techniques.
|
through study completion, an average of ~8 months
|
Effect of treatment on hemoglobin levels
Time Frame: through study completion, an average of ~8 months
|
Hemoglobin level of patients (in g/L) will be measeured at every patient visit, and their longitudinal change will be analyzed using mixed-effect statistical modeling techniques.
|
through study completion, an average of ~8 months
|
Effect of treatment on hematocrit levels
Time Frame: through study completion, an average of ~8 months
|
Hematocrit level of patients (in L/L) will be measeured at every patient visit, and their longitudinal change will be analyzed using mixed-effect statistical modeling techniques.
|
through study completion, an average of ~8 months
|
Number of treatments where the planned power output of the Oncotherm EHY-2030 device could not be reached
Time Frame: 3 months
|
For an optimal treatment, the Oncotherm EHY-2030 device must reach its maximum output for 30 minutes.
The number of treatments where this optimal outpur could not be reached will be reported.
|
3 months
|
Longitudinal analysis of the EORTC QLQ-C30 questionnaire's total scores
Time Frame: through study completion, an average of ~8 months
|
The European Organisation for Research and Treatment of Cancer 30-item quality of life questionnaire for cancer patients (EORTC QLQ-C30) total scores will be calculated as per the official quidelines, and their longitudinal change will be analyzed using mixed-effect statistical modeling techniques. Scoring of the questionnaire will be performed as per the official instructions of EORTC |
through study completion, an average of ~8 months
|
Longitudinal analysis of the EORTC QLQ-BR23 questionnaire's total scores
Time Frame: through study completion, an average of ~8 months
|
The European Organisation for Research and Treatment of Cancer 23-item quality of life questionnaire for breast cancer patients (EORTC QLQ-BR23) total scores will be calculated as per the official quidelines, and their longitudinal change will be analyzed using mixed-effect statistical modeling techniques. Scoring of the questionnaire will be performed as per the official instructions of EORTC |
through study completion, an average of ~8 months
|
Longitudinal analysis of the EQ-5D-5L questionnaire scores
Time Frame: through study completion, an average of ~8 months
|
The questionnaire will be assessed as per official guidelines. EuroQol's 5-dimension health-related quality of life instrument (EQ-5D-5L) questionnaire scores' longitudinal change will be analyzed using mixed-effect statistical modeling techniques. Scoring of the questionnaire will be performed as per the official instructions of EuroQol. |
through study completion, an average of ~8 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Treatment-Emergent Adverse Events as assessed by the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.
Time Frame: through study completion, an average of ~8 months
|
All adverse events will be assessed and classified by the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. Using descriptive statistics, the number of occurrances will be listed for both study arms. |
through study completion, an average of ~8 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Magdolna Dank, M.D./Ph.D., Semmelweis University
Publications and helpful links
General Publications
- Szasz AM, Minnaar CA, Szentmartoni G, Szigeti GP, Dank M. Review of the Clinical Evidences of Modulated Electro-Hyperthermia (mEHT) Method: An Update for the Practicing Oncologist. Front Oncol. 2019 Nov 1;9:1012. doi: 10.3389/fonc.2019.01012. eCollection 2019.
- Herold Z, Szasz AM, Dank M. Evidence based tools to improve efficiency of currently administered oncotherapies for tumors of the hepatopancreatobiliary system. World J Gastrointest Oncol. 2021 Sep 15;13(9):1109-1120. doi: 10.4251/wjgo.v13.i9.1109.
- Petenyi FG, Garay T, Muhl D, Izso B, Karaszi A, Borbenyi E, Herold M, Herold Z, Szasz AM, Dank M. Modulated Electro-Hyperthermic (mEHT) Treatment in the Therapy of Inoperable Pancreatic Cancer Patients-A Single-Center Case-Control Study. Diseases. 2021 Nov 3;9(4):81. doi: 10.3390/diseases9040081.
- Szasz AM, Arrojo Alvarez EE, Fiorentini G, Herold M, Herold Z, Sarti D, Dank M. Meta-Analysis of Modulated Electro-Hyperthermia and Tumor Treating Fields in the Treatment of Glioblastomas. Cancers (Basel). 2023 Jan 31;15(3):880. doi: 10.3390/cancers15030880.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Neoplasms
- Neoplasms by Site
- Wounds and Injuries
- Breast Diseases
- Body Temperature Changes
- Heat Stress Disorders
- Breast Neoplasms
- Hyperthermia
- Fever
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antirheumatic Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Antineoplastic Agents, Phytogenic
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Antibiotics, Antineoplastic
- Cyclophosphamide
- Carboplatin
- Paclitaxel
- Doxorubicin
Other Study ID Numbers
- NeoHTerMa
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HER2-negative Breast Cancer
-
Peregrine PharmaceuticalsWithdrawnBreast Cancer | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | Triple-Negative Breast Cancer | Triple-Negative Breast Neoplasm | ER-Negative PR-Negative HER2-Negative Breast Neoplasms | ER-Negative PR-Negative HER2-Negative Breast Cancer
-
Masonic Cancer Center, University of MinnesotaActive, not recruitingTriple Negative Breast Cancer | HER2-positive Breast Cancer | TN ER-/PR-/HER2- Breast Cancer | ERany/PRany/HER2+ Breast CancerUnited States
-
AIO-Studien-gGmbHNovartis Pharmaceuticals; iOMEDICO AGCompletedHer2-negative Metastatic Breast Cancer | Her2-negative Locally Advanced Breast CancerGermany
-
Fudan UniversityRecruitingBreast Cancer | Breast Neoplasm | Breast Tumors | HER2-positive Breast Cancer | Locally Advanced Breast Cancer | HER2-negative Breast Cancer | Hormone Receptor Positive Tumor | Hormone Receptor Negative Tumor | Early-stage Breast Cancer | Triple-Negative Breast Cancer (TNBC)China
-
QuantumLeap Healthcare CollaborativeRecruitingSolid Tumor | Metastatic Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | HER2-positive Breast Cancer | Solid Tumor, Adult | Solid Carcinoma | HER2-positive Metastatic Breast Cancer | Progesterone Receptor-positive Breast Cancer | HER2-negative Breast Cancer | Estrogen Receptor Positive... and other conditionsUnited States
-
Massachusetts General HospitalGilead SciencesRecruitingTriple Negative Breast Cancer | Invasive Breast Cancer | HER2-negative Breast Cancer | ER-Negative Breast Cancer | PR-Negative Breast CancerUnited States
-
Cancer Trials IrelandCompletedBreast Cancer | HER2 Positive Breast Cancer | HER2 Negative Breast CancerIreland
-
UNC Lineberger Comprehensive Cancer CenterNational Cancer Institute (NCI); Syndax PharmaceuticalsTerminatedBreast Cancer | Invasive Breast Cancer | ER-Negative PR-Negative HER2-Negative Breast CancerUnited States
-
H. Lee Moffitt Cancer Center and Research InstituteThe Shulas' FoundationRecruitingTriple Negative Breast Cancer | HER2-negative Breast CancerUnited States
-
German Breast GroupGilead Sciences; ETOP IBCSG Partners Foundation; UNICANCER; Austrian Breast & Colorectal... and other collaboratorsRecruitingTriple Negative Breast Cancer | HER2-negative Breast CancerSpain, France, Germany, Austria, Belgium, Ireland, Italy, Switzerland
Clinical Trials on Paclitaxel
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingRecurrent Breast Carcinoma | Stage IV Breast Cancer AJCC v6 and v7 | Stage III Breast Cancer AJCC v7 | Stage IIIA Breast Cancer AJCC v7 | Stage IIIB Breast Cancer AJCC v7 | Stage IIIC Breast Cancer AJCC v7 | Metastatic Breast Carcinoma | Locally Advanced Breast CarcinomaUnited States
-
Hutchison Medipharma LimitedSun Yat-sen UniversityActive, not recruitingAdvanced Gastric CancerChina
-
University of WashingtonNational Cancer Institute (NCI); Celgene CorporationCompletedRecurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung CancerUnited States
-
Anne NoonanNational Cancer Institute (NCI)RecruitingStage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic AdenocarcinomaUnited States
-
Shengjing HospitalRecruiting
-
CTI BioPharmaTerminatedNSCLCUnited States, Canada, Bulgaria, Romania, Russian Federation, Ukraine, Mexico, Argentina, Hungary, Poland, United Kingdom
-
Mayo ClinicNational Cancer Institute (NCI)WithdrawnRecurrent Bladder Urothelial Carcinoma | Stage IV Bladder Urothelial CarcinomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingAnatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditionsUnited States
-
CTI BioPharmaTerminated
-
Novartis PharmaceuticalsCompletedMetastatic or Locally Advanced Solid TumorsNetherlands, Spain, Germany, Switzerland, Belgium